Omalizumab for asthma
is a topic covered in the Evidence-Based Medicine Guidelines
To view the entire topic, please sign in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
"Omalizumab for Asthma." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/455460/all/Omalizumab_for_asthma.
Omalizumab for asthma. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/455460/all/Omalizumab_for_asthma. Accessed October 17, 2019.
Omalizumab for asthma. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/455460/all/Omalizumab_for_asthma
Omalizumab for Asthma [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2019 October 17]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/455460/all/Omalizumab_for_asthma.
TY - ELEC
T1 - Omalizumab for asthma
ID - 455460
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/455460/all/Omalizumab_for_asthma
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine